MCF7aro Let-R Cell Line
Invented at Royal College of Surgeons Ireland
- Datasheet
- References (5)
- Inventor Info
Info
Catalogue Number | 151781 |
Antigen/Gene or Protein Targets | Aromatase expressing, Letrozole resistant |
Parental Line | MCF7 |
Host | Human |
Tissue | Breast |
Disease Keywords | Breast cancer |
Model | Tumour line |
Relevance | MCF7aro Let-R Cell Line is a human cell line model of aromatase inhibitor resistant breast cancer. |
Production Details | Letrozole (aromatase inhibitor) sensitive cells (MCF-7aro) were developed by stable transfection of the aromatase gene (CYP19); Letrozole-resistant cells (MCF-7aro Let-R) were created by long-term treatment of aromatase-expressing MCF7 cells (MCF7aro) with letrozole. |
Research Area | Cancer, Drug Discovery & Development |
Recommended Growing Conditions | They are cultured in phenol red free Eagle’s Minimum Essential Medium (Phenol-red free MEM) (Sigma Aldrich), 10% charcoal dextran stripped FCS (CDS-FCS), 1% Pen-Strep (Sigma Aldrich), 2 mM L-Glutamine (Sigma Aldrich) and 200 µg/ml G418 disulfate salt (Geneticin) (Sigma Aldrich), 2.5-8 M androstenedione and 10-6 M letrozole. |
Cellosaurus ID | CVCL_W348 |
References: 5 entries
Cellosaurus MCF-7aro Let-R (CVCL_W348)
O'Hara et al. 2012. Clin Cancer Res. 18(12):3305-15. PMID: 22550166.
AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
Europe PMC ID: 22550166
McIlroy et al. 2010. Cancer Res. 70(4):1585-94. PMID: 20145129.
Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
Europe PMC ID: 20145129
Add a reference
References: 5 entries
Cellosaurus MCF-7aro Let-R (CVCL_W348)
O'Hara et al. 2012. Clin Cancer Res. 18(12):3305-15. PMID: 22550166.
AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
McIlroy et al. 2010. Cancer Res. 70(4):1585-94. PMID: 20145129.
Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
Add a reference